News

Jennifer I. Lim, MD, FARVO, FASRS shared insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis" with our team.

Lim and colleagues conducted a retrospective study to establish the normalized NBFI using OCTA and test if that index is sufficiently sensitive for detecting early DR.

The American Society of Retina Specialists is hosting its annual meeting this year in Seattle, Washington. Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.

Detrimental effects of IVB may not be recognized at an early age, which underscores the importance of following these children over time.

With this funding, the DISCOVER study will evaluate the safety and tolerability of three doses of AXT107 in patients with wet AMD.

Using automated methods to determine the visual acuity showed robust performance in predicting visual impairment.

APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy.

THR-149 is being evaluated in a Phase 2 clinical trial as a potential treatment for diabetic macular edema, which is expected to readout topline results by the end of this year.

The results of this study demonstrated the good safety and tolerability of HLX04-O.

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease.

The companies plant to create a comprehensive resource that provides valuable insights into health outcomes, medication adherence, and the effectiveness of various treatment protocols.

Clearside Biomedical developing a long-acting therapy for the treatment of retinal diseases, including wet AMD.

DAYLIGHT is the first of the company's 3 studies and was a randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of a high-intensity dosing regimen of tarcocimab tedromer.

Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists 2023 annual meeting in Seattle, Washington, including a late-breaking presentation on Vabysmo’s effect on epiretinal membrane (ERM) formation in DME compared to aflibercept.

The DR:EAM trial will evaluate topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

According to 4DMT, the Dose Expansion stage of the PRISM trial is a multicenter, randomized study designed to evaluate the safety and efficacy of 4D-150 at two different dose levels.

Harrow states that this transaction will grant US and Canadian commercial rights to six therapeutics, including two non-prescription brands.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

Eye drops developed by Columbia University researchers could prove to be a more effective and comfortable therapy for retinal vein occlusion (RVO).

Nominations for the 2023 awards will close July 31, 2023.

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.

The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.

Tenpoint’s aim is to reverse vision loss by generating specialized ocular cell types, both ex vivo and in vivo.

Cognition Therapeutics has dosed the first participant in the phase 2 MAGNIFY study of CT1812. This oral therapy is being studied as a for geographic atrophy (GA) secondary to dry age-related macular edema (AMD).

Akari remains on track and plans to submit an IND application to the US FDA in the first half of 2024, and plans on starting clinical trials in the second half of 2024

R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.